
New research points to the potential of a COVID-19 vaccine delivered through the nose. The phase 1 clinical trial showed that the product, administered nasally in two doses, delivered a significant immune response to multiple COVID variants. Called CoviLiv, the vaccine was tested as a primary vaccination series on healthy adults before development of the… read on > read on >